The YELLOWSTONE Induction 1 and 2 studies are phase 3, randomized, double-blind, placebo-controlled, multicenter studies that will evaluate the efficacy and safety of ozanimod (also known as RPC1063), an investigational oral medication being studied for individuals with moderately to severely active Crohn’s disease.
The YELLOWSTONE Induction 1 and 2 studies are phase 3, randomized, double-blind, placebo-controlled, multicenter studies that will evaluate the efficacy and safety of ozanimod (also known as RPC1063), an investigational oral medication being studied for individuals with moderately to severely active Crohn’s disease.
The YELLOWSTONE Induction 1 and 2 studies are phase 3, randomized, double-blind, placebo-controlled, multicenter studies that will evaluate the efficacy and safety of ozanimod (also known as RPC1063), an investigational oral medication being studied for individuals with moderately to severely active Crohn’s disease.